GPX4 and neoplasm: This timing dependence is clearly demonstrated by Efimova’s team, who showed that the GPX4 inhibitor RAS-Selective Lethal compound 3 (RSL3) stimulated ICD in tumor cells to activate DCs and induce anti-tumor immunity in an animal tumor model (40).